B
BCAX
Bicara Therapeutics
16.61
-0.68-3.93%Opening12:41 10/06 EDT
OPEN/PREV CLOSE17.43/17.29
TODAY RANGE16.47-17.52
VOL325.35K
MARKET CAP1.10B
52 WEEK RANGE13.70-30.99
AVG VOL (3M)623.13K
% TURNOVER0.49%
TURNOVER--
P/E (TTM)-5.3831
% RANGE6.07%
EPS(TTM)-3.0856
P/E(FORWARD)-4.8355
P/B2.336
BVPS7.11
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP935.30M
SHARES OUTSTANDING66.17M
NEXT EARNINGS11/09-11/13
FREE FLOAT56.31M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·08/25 21:17
Bicara Therapeutics Secures Boston Headquarters Through Sublease
Dow Jones·08/19 10:07
Bicara Therapeutics Initiated at Outperform by BMO Capital
Dow Jones·08/19 10:07
Bicara Therapeutics Price Target Announced at $35.00/Share by BMO Capital
TipRanks·08/18 20:35
BMO starts Bicara at Outperform, sees meaningful upside potential
TipRanks·08/18 20:25
Bicara Therapeutics initiated with an Outperform at BMO Capital
TipRanks·08/17 09:55
Bicara Therapeutics price target raised to $20 from $18 at Mizuho
TipRanks·08/17 09:37
Bicara Therapeutics price target raised to $39 from $37 at Morgan Stanley
TipRanks·08/13 14:37
Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
TipRanks·08/13 12:16
Mizuho Securities Reaffirms Their Hold Rating on Bicara Therapeutics Inc. (BCAX)
Dow Jones·08/12 18:33
Bicara Therapeutics Price Target Raised to $20.00/Share From $18.00 by Goldman Sachs
Dow Jones·08/12 18:33
Bicara Therapeutics Is Maintained at Neutral by Goldman Sachs
Same Industry
Name/Symbol
Change%
Price